Total amount: € 0,00
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,236
Online ISSN 1827-1669
Li LIU 1, Wuhua GUO 1, Jixiang ZHANG 1, 2
1 The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, P.R. China; 2 Jiangxi Province Key Laboratory of Molecular Medicine, Nanchang, Jiangxi, P.R. China
INTRODUCTION: The study aimed to assess the association between human leukocyte antigen (HLA)-DRB1 allele polymorphisms and hepatocellular carcinoma (HCC) susceptibility.
EVIDENCE ACQUISITION: Relevant case-control studies on HLA-DRB1 allele correlation with HCC risk published between 2000 and 2015 were searched and retrieved in literature database. The odds ratio (OR) with its 95% confidence interval (CI) were employed to calculate the strength of association. Total 16 articles including 2208 HCC patients and 3028 relevant controls were finally screened out.
EVIDENCE SYNTHESIS: Thirteen alleles (HLA-DRB1*01, *03, *04, *07, *08, *09, *10, *11, *12, *13, *14, *15, and *16) were reported. Overall, we found that HLA-DRB1*11, *12, *13 and *14 allele polymorphisms were significantly associated with HCC development (*11: OR=0.62, 95% CI=0.42-1.91, P=0.02; *12: OR=1.45, 95% CI=1.08-1.94, P=0.01; *13: OR=0.67, 95% CI=0.46-0.97, P=0.03; *14: OR=1.61, 95% CI=1.10-2.35, P=0.01) in a fixed-effect model. Subgroup analysis by ethnicity showed that *12 and *14 allelic polymorphisms were related with HCC susceptibility in Asian but not in Caucasian or African. Furthermore, other HLA-DRB1 allele polymorphisms were not associated with increased the risk of HCC (P>0.05).
CONCLUSIONS: HLA-DRB1*11, *12, *13 and *14 allele polymorphisms were risk factors for HCC development. Future large-scale studies with more ethnicities are still needed.